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Abstract 
Objective 
We sought to assess the effectiveness of clozapine augmentation with ECT (C+ECT) in 
patients with clozapine-resistant schizophrenia.  
Methods 
We conducted a retrospective review of electronic health records to identify patients treated 
with C+ECT. We determined the response to C+ECT and the rate of rehospitalisation over 
the year following treatment with C+ECT. 
Results 
Forty-two patients were treated with C+ECT over a ten year period. The mean age of the 
patients at initiation of ECT was 46.3 (SD=8.2) years (range 27-62 years). The mean 
number of ECTs given was 10.6(SD = 5.3)(Range 3-25) with the majority receiving twice 
weekly ECT.  Seventy six percent of patients (n=32) showed a Clinical Global Impression 
improvement score (CGI-I) of≤3 (at least minimally improved) following C+ECT. The mean 
number of ECT treatments was 10.6 (SD = 5.3) (range 3-25) with the majority receiving 
twice weekly ECT.   Sixty four percent of patients experienced no adverse events. Response 
to C+ECT was not associated with gender, age, duration of illness, or duration of clozapine 
treatment. 
Seventy five percent of responders remained out of hospital over the course of one-year 
follow up, while 70% of those with no response to C+ECT were not admitted to hospital. 
Three patients received maintenance ECT, one of whom was rehospitalised.   
	   4	  
Conclusion 
This study lends support to emerging evidence for the effectiveness of C+ECT in clozapine 
resistant schizophrenia. These results are consistent with the results of a meta-analysis and 
the only randomised controlled trial (RCT) of this intervention. Further RCTs are required 
before this treatment can be confidently recommended. 
Keywords: 
Schizophrenia; treatment-resistant; electroconvulsive therapy; psychosis;clozapine 
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Significant outcomes 
Highlights 
• Our study adds to the small extant literature indicating that clozapine 
augmentation with ECT (C+ECT) is associated with a high response rate, with 
76% showing an acute response 
• Our study findings indicate that the response to C+ECT is maintained in a majority 
of patients (75% remained out of hospital) with continued clozapine use over 1 
year follow up (although 70% of non responders were not admitted to hospital) 
• This is the largest retrospective study of C+ECT use in TRS and provides further 
evidence of the effectiveness of C+ECT in those with clozapine resistant 
schizophrenia 
Limitations 
Retrospective study, with no blinding, lack of a control arm and concurrent medication 
use was not controlled 
Longer term follow up studies with larger sample sizes receiving M+ECT are required to 
evaluate the effectiveness of M+ECT in clozapine resistant schizophrenia  
It was not possible to evaluate patient perspectives and experiences of ECT 
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Introduction 
Treatment resistant schizophrenia (TRS) is the most disabling of all psychiatric illnesses and 
affects approximately 30% of those diagnosed with schizophrenia (Meltzer 1997, Lally et al., 
2016a). Clozapine remains the treatment of choice for people with TRS, with approximately 
50-60% of patients improving with clozapine (Meltzer 1992, Agid et al., 2011). There remain 
no evidence based pharmacological treatments for the remaining 40-50% of treatment 
resistant patients who fail to respond to clozapine (Taylor 2017, Lally and MacCabe 2015) 
(Lally and Gaughran 2019).   
Meta-analyses have failed to demonstrate efficacy for clozapine augmentation with 
psychotropic medication, including antipsychotics and mood stabilisers (Sommer et al., 
2012). However, a recent randomised controlled trial (RCT) of clozapine augmentation with 
ECT (C+ECT) in clozapine-resistant schizophrenia showed encouraging results (Petrides et 
al., 2015). Combining the results of that RCT with those of all other cases reported in the 
literature, we calculated the response rate for C+ECT in TRS to be 66% (Lally et al., 2016b). 
Another meta-analysis demonstrated that ECT combined with non-clozapine antipsychotics 
was superior to antipsychotic monotherapy in TRS (Zheng et al., 2016), supporting the 
findings of an earlier Cochrane review on ECT in schizophrenia which concluded that ECT is 
effective in schizophrenia and may have a place in patients who have failed to respond to 
other treatments (Tharyan and Adams 2005). The most recent Cochrane review of ECT for 
clozapine resistant schizophrenia found moderate evidence for improved clinical with C-ECT 
use compared to standard care (Sinclair et al., 2019). These studies suggest a benefit of 
ECT in TRS, in the short term, but data on longer-term outcomes are almost completely 
lacking (Grover et al., 2019). A systematic review of the use of maintenance ECT (M-ECT) in 
non TRS, identified that while quality evidence is lacking, M-ECT has some evidence for 
relapse prevention in combination with antipsychotics, with minimal evidence for persistent 
cognitive deficits (Ward et al., 2018). It is also unclear whether maintenance ECT is needed 
to maintain improvement following response to C+ECT in TRS. 
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Study aims 
The primary aim of this retrospective study was to describe the short term outcomes in a 
cohort of patients treated with C+ECT. The secondary aims were: 1) to explore the medium-
term outcome of patients who received C+ECT based on the rate of psychiatric 
rehospitalisation in the year following a successful response to C+ECT, 2) to examine and 
identify post-ECT treatments which maintain clinical response, 3) to describe the use of 
maintenance ECT in those initial responders to C+ECT and 4) to evaluate adverse effects 
associated with C+ECT. 
Methods 
This was a retrospective observational study performed using data from the Clinical Record 
Interactive Search (CRIS) database from the South London and Maudsley (SLaM) NHS 
Foundation Trust. 
In this study, we described the response to treatment in patients receiving ECT to augment 
clozapine (i.e. clozapine is continued during ECT). The primary outcome was the overall 
improvement in symptoms based on the Clinical Global Impression improvement  (CGI-i) 
scale (Guy (1976)).  
Data Source 
Serving over 1.2 million residents located in four London boroughs (Croydon, Lambeth, 
Lewisham and Southwark), the SLaM NHS Foundation Trust is the largest provider of 
mental healthcare in Europe. Clinical records dating back to 1 January 2007 are stored in a 
combination of structured free text fields. In August 2016 there were over 200,000 
individuals records.  
The Clinical Record Interactive Search (CRIS) system was developed by the National 
Institute for Health Research Biomedical Research Centre located within the SLaM NHS 
trust to enable the automated search and retrieval of anonymised patient records. Data from 
structured text fields or from free text within the clinical records (e.g. clinical progress notes, 
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discharge summaries, outpatient correspondence) was extracted. Comprehensive details 
regarding this data resource can be found in an open access publication.(Stewart et al., 
2009)  
Ethics and CRIS approval 
Oxfordshire Research Ethics Committee C granted ethical approval to CRIS as an 
anonymised data resource for secondary analysis in 2008. A patient-led oversight committee 
is responsible for the governance for all CRIS project, who report to the SLaM Caldicott 
Guardian. This study carried CRIS application number 16-018 and was approved on 17th 
March 2016. 
Inclusion and exclusion criteria 
Primary inclusion and exclusion 
The primary inclusion criterion was any person who received ECT to augment clozapine 
response, as part of a treatment plan for schizophrenia, or schizoaffective disorder (ICD-10 
codes: F20.0. F25.0, respectively), and whose records contained sufficient information to 
retrospectively rate their response to treatment and had at least one year’s follow up data. 
The treating clinicians defined an inadequate clozapine response and identified the need for 
ECT augmentation. The decision to begin and end ECT was made by the Consultant Psychiatrist 
responsible for the care of the patient, in consultation with the treating team and the patient. There 
was no age range criterion.  
Figure 1 shows the flowchart for inclusion in the study.  
Data extraction and Outcome variables 
The first ECT treatment registered for each patient admitted during this 10-year period was 
defined as the index treatment. The following data were obtained for each patient: gender, 
age, ethnicity, diagnosis, duration of illness, duration of clozapine treatment, duration of 
	   9	  
current episode (the episode that warranted ECT treatment), indication for ECT treatment, 
duration, number and frequency of ECT treatments, clozapine dose concurrent to ECT, other 
concurrent medications at time of ECT, outcome of ECT treatment, adverse events, 
subsequent use of maintenance ECT, subsequent prescription of maintenance medications 
(including subsequent prescription of clozapine, including dose changes and clozapine 
augmentation), subsequent rehospitalisation post response to C+ECT, and ECT treatment 
details.  
The patient clinical records did not contain any standardised assessments of severity of 
illness or degree of improvement. CGI scores were retrospectively assigned based on 
documented clinical symptoms, psychopathology, behaviour, and functioning identified from 
the clinical records for 1 week prior to the administration of ECT and for one week after the 
end of the acute ECT course. As symptoms and behaviour can vary over the course of a 
week; the score was assigned based on the average severity level documented across the 
seven days. The CGI scores were rated by one of the researchers (EB) and were then 
checked for reliability by a clinician (JL). Consensus was sought where any differences 
existed and a final CGI score was recorded. We compared the mean and median CGI-
severity (CGI-S) scores at the start and end of C+ECT. 
A dichotomous response criterion based on the Clinical Global Impression (CGI) -
Improvement scale was recorded for each ECT treatment case, using records from baseline 
(i.e. prior to C+ECT) and at the end of the ECT course. The CGI-Improvement (CGI-I) scale 
score was recorded following the end of C+ECT to assess the overall improvement and 
response (or not) to C+ECT. Any improvement (a rating of 1, 2 or 3) was seen as a 
successful response and a decline or no change (anything rated 4, 5, 6 or 7) was deemed 
unsuccessful (4= no change seen).  
Statistical analysis 
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Descriptive statistics were performed using summary statistics (mean, standard deviation, 
median and range) for quantitative variables and frequencies for binary and nominal 
variables. The associations between demographic and clinical variables and response to 
C+ECT were assessed using t tests, or chi-square tests as appropriate, with a two-tailed 
alpha of 0.05.  
 
Results 
Demographic and clinical characteristics  
A total of 42 patients (21 males) were treated with C+ ECT. The mean age of the patients at 
initiation of ECT was 46.3 (SD=8.2) years (range 27-62 years). Out of the total 42 
participants, 29 (69%) were of white ethnicity, 12(29%)  of black ethnicity and one (2%) was 
of mixed ethnicity.  
Thirty-five (83%) patients had a diagnosis of schizophrenia and 7 (17%) had a diagnosis of 
schizoaffective disorder.  
The mean clozapine dose during C+ECT was 383.7 (SD=211.6) mg. The mean duration of 
illness and clozapine administration were 5.5 (SD=5.0) years (median =4.3 years; 
range=.26-20.6 years) and 2.8 (SD=3.2) years (median 2.8 years; range =0.08-14.9 years) 
respectively. The mean duration of the current psychotic episode was 9.2 (SD=13.3) months 
(range =11 days-4.6 years). The median duration was 3.3 months. 
ECT and clinical outcomes  
The clinical indication for ECT augmentation in all cases was an insufficient response to 
clozapine (n=42/42). All patients received bilateral ECT (the stimulus dose was not 
consistently recorded). The mean number of ECT treatments was 10.6 (SD = 5.3) 
(median=10) (Range 3-25 ECT treatments (the majority of patients received twice weekly 
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ECT (n=17)). The mean duration of ECT treatment was 8.4 (SD=7.0) weeks. Females 
received a higher mean number of ECT treatments (mean=12.4 (SD=5.6) compared to 
males (mean =8.7 (SD=4.4)) (t(35)=2.221,p=0.033).  
Thirty two patients (76%) responded to C+ECT (CGI-I ≤3). Eleven (26%) were ‘very much’ or 
‘much’ improved following C+ECT.  The CGI-I stratified by gender and for the total group is 
shown in table 1.  
INSERT TABLE 1 HERE 
There was a significant improvement in mean CGI-s scores following C+ECT (pre C+ECT 
=4.8 (SD=0.8) and post C+ECT 3.8 (SD=0.93) (t=7.117, df=41, p<0.001). There was no 
significant difference in mean clozapine dose during C+ECT in those who responded to 
C+ECT (mean dose= 379.4 (SD=223.6) mg ) compared those who did not respond (mean 
dose =397.5 (177.3) mg) (t=0.234, p=0.816).  Associations between clinical characteristics 
and age, and response to C+ECT are shown in table 2.  
INSERT TABLE 2 HERE 
Adverse events 
Most individuals did not have any adverse effects secondary to ECT (64% (27/42) with no 
recorded adverse effects).  Nine patients reported short term memory loss concurrent to 
ECT treatment which was transient for all and occurred at the time of the C+ECT.  
Medication use concurrent to C+ECT 
The response to C+ECT in relation to concurrent medications used at the time of C+ECT is 
shown in table 3. The use of anticonvulsant medication or benzodiazepines concurrent to 
C+ECT was not associated with a decreased response to C+ECT.  
INSERT TABLE 3 HERE 
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Rehospitalisation post ECT response  
Of the 32 patients who responded favourably to C+ECT, there were (n=5, 16%) who 
required rehospitalisation during the following year. Seventy five percent (n=24) of 
responders were not hospitalised over the course of the one year follow up (and 3 remained 
hospitalised during the follow up year). Thirty percent (n=3) of those with a non-response to 
C+ECT were rehospitalised over the follow up period. 
Time to rehospitalisation (n=29 who were discharged post response to C+ECT) 
Five of those who responded to C+ECT were rehospitalised due to illness relapse over the 
next year. The mean time to rehospitalisation was 106.8 days (range =24-280 days) and the 
median was 83 days.  
In the year following response to C+ECT, 21% (n=6) of responders were treated with 
clozapine combined with antidepressant medication, 31% (n=9) were treated with clozapine 
augmented with mood stabilisers, 69% (n=18) had a dose increase in clozapine over the 
course of the year following ECT 
There was no significant association between the use of clozapine combined with mood 
stabilisers (x2=2.719, p=0.131), antidepressant (x2=1.576, p=0.283) or M-ECT use 
(x2=0.607, p=0.446) and rehospitalisation. 
In total, 21 of the responders to C+ECT had either a dose increase in clozapine (n=17), were 
treated with M-ECT (n=1), were treated with both a clozapine dose increase and M-ECT 
(n=1), or were rehospitalised (with no clozapine dose increase or M-ECT use) (n=2). 
Discussion 
Response to C+ECT 
Seventy six percent of patients had a positive response to C+ECT, a similar response rate to 
that identified in other retrospective case series ( 66%(Grover et al., 2017)- 69%(Kim et al., 
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2017)); though slightly lower than the 90% of patients who had an excellent or very good 
response in the study of Kristensen et al., (Kristensen et al., 2011). Our response rate is 
slightly higher than the previously identified pooled response rate of 66% to C+ECT in all 
extant published data (Lally et al., 2016b). Thirty four percent of responders were very much 
or much improved following C+ECT.  
Rehospitalisation post C+ECT 
The one year rehospitalisation rate was 17% in those who were discharged post response to 
C+ECT, compared to 30% in those who did not respond to C+ECT, indicating that the acute 
response to C+ECT was associated with a low rehospitalisation rate over the following year. 
A recent Taiwanese mirror-image study using a national healthcare database, investigated 
the rates of psychiatric hospitalisation, following antipsychotic augmentation with ECT in 
patients with schizophrenia receiving ECT for the first time. They identified that antipsychotic 
augmentation with ECT was associated with a reduced rate of psychiatric hospitalization in 
the year following treatment, a finding that was particularly significant for those treated with 
C+ECT (n=906) (Lin et al., 2017). 
M+ECT and rehospitalisation during follow up 
During follow up, 72% of responders had a dose increase in clozapine, were commenced on 
maintenance ECT (M-ECT) or were rehospitalised over the year following C+ECT. Dose 
increases in clozapine may have been indicative of re-emerging psychotic symptoms, 
though only one of these patients was rehospitalised (and this coincided with the 
commencement of M-ECT). We were unable to identify any significant relationship between 
concurrent medication use during the follow up period and reduced rates of hospitalisation, 
though it is of interest that all those patients treated with clozapine and mood stabilisers, or 
with antidepressants were not rehospitalised in the year following C+ECT. The proportion of 
responders who were later treated with M-ECT is similar to that identified in the follow up 
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study of Grover et al., (Grover et al., 2017) though fewer than the 35% identified in a Danish 
retrospective chart review (Kristensen et al., 2011).  
The low rate of rehospitalisation following a response to C+ECT, is equivalent to the 
maintained response rates of 66% shown in the retrospective review of Grover et al., 
(though they do not comment on dose changes in clozapine, rather documenting that 66% 
maintained their improvement while concurrently treated with clozapine) (Grover et al., 
2017), or the 65% of those who did not require M-ECT for relapse of symptoms in the 
Kristensen et al., retrospective chart review (Kristensen et al., 2011). An earlier open label 
study of 11 patients treated with C+ECT identified a relapse rate of 63% over an average 
follow up of 14 weeks following response to C+ECT (Kho et al., 2004). 
Only 3 of those who responded to C+ECT received M-ECT, with only one of those requiring 
hospitalisation for the administration of the maintenance treatment. Those treated with M-
ECT were treated with 10-20 ECT treatments, two of whom were treated with weekly ECT, 
and the third patient was treated with weekly M-ECT for seven weeks followed by twice 
monthly ECT for 7 treatments. Due to the small number of patients who received M-ECT, we 
are unable to comment on the effectiveness of the adjunctive treatment in our population. 
Open label studies have provided support for sustained treatment effects with M-ECT. A 
previous open label study (n= 23) identified that 48% of those with clozapine resistant 
schizophrenia had a clinical response to acute C+ECT, and subsequently found an improved 
sustained clinical response with M-ECT compared to those treated with acute ECT and no 
maintenance ECT alongside continued clozapine(Youn et al., 2019). An open pilot study 
(n=14) providing M-ECT for those who responded to ECT for clozapine resistant 
schizophrenia as part of a cross over RCT, showed no deterioration, and the clinical 
response was sustained for all who received M-ECT for a 6 month period (n=6, completed 
course of  10 C+ECT treatments in 6 months following acute C+ECT) (Braga et al., 2019). 
ECT treatment and associations with response 
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The mean number of ECT treatments was 10.6, consistent with that identified in the 
retrospective chart review of C+ECT of Kristensen et al., (=10) (Kristensen et al., 2011), and 
the mean number of 11.3 identified in a recent meta-analysis of C+ECT (Lally et al., 2016b). 
The number of ECT treatments was not significantly associated with treatment response or 
non-response. The duration of illness or the current psychotic episode was not associated 
with the likelihood of a patient responding, similar to findings of a retrospective chart review 
of the use of ECT in schizophrenia (Kristensen et al., 2011). 
Adverse events 
The use of C+ECT was generally well tolerated with most patients reporting no adverse 
events, although this may be an underestimate due to underreporting of adverse events and 
under-recording in the clinical records. There was no evidence of prolonged seizures in any 
of the patients, though transient memory problems were reported in 21%, these were not 
sustained. A limitation of this study is the lack of formal cognitive testing performed, 
preventing a quantitative assessment of any cognitive changes over the course of C+ECT. 
One patient was found to have evidence of an underlying pre-existing neurocognitive 
disorder, which was identified during C+ECT.  
Limitations 
The findings from this naturalistic cohort, while demonstrating that C+ECT is effective for 
over 3/4s of patients, needs to be viewed considering certain limitations. The retrospective 
nature of the study design and the absence of a comparison group limit the conclusions that 
can be drawn. Furthermore, it was not possible to blind the ratings, so there is a possibility of 
observer bias. The retrospective nature of assigning clinical assessment scores, and the 
lack of prospective measures of clinical state such as PANSS or BPRS is a further limitation 
and potential source of observer bias. The CGI-S and CGI-I scales are brief assessment 
tools, that allow for retrospective assessment of clinical states and improvement, though 
which may not adequately assess the severity of psychotic symptoms. However, the CGI 
	   16	  
assess both symptom severity and functioning, which may make it more relevant to clinical 
practice than the PANSS or BPRS that assess symptom severity only. The small sample 
size may have limited the power of our study to make statistical inferences and raising the 
possibility of type II errors, though it remains one of the largest clinical cohorts assessing the 
use of C+ECT in clinical practice. The lack of a control group limited the ability to conduct 
statistical analysis of clinical effects. The lack of neurocognitive assessments is a limitation, 
particularly since 21% of patients reported some transient memory loss concurrent to 
C+ECT. 
There are limited studies investigating the response to C+ECT in clozapine refractory TRS, 
and even fewer studies with longer term follow up data. (Kristensen et al., 2011, Grover et 
al., 2017, Petrides et al., 2015, Meltzer 1997, Braga et al., 2019) Our findings indicate that 
C+ECT is associated with a high response rate, and is well tolerated. The use of clozapine 
dose increases was a commonly used treatment intervention in the year post C+ECT; 
though no specific medication intervention was associated with a significantly reduced risk of 
rehospitalisation. Our study adds to the small, but growing literature indicating that C+ECT 
may be an effective treatment for clozapine refractory schizophrenia, although our results 
need to be viewed with caution in the light of the methodological limitations. 
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Table 1. Outcome of clozapine augmentation with ECT measured by CGI scores 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CGI-
Improvement  
Score 
1-Very 
much 
improved 
2-Much 
improved 
3-
Minimally 
improved 
4-No 
change 
5-
Minimally 
worse 
6-
Much 
worse 
7-Very 
much 
worse 
        
Men 1 4 9 5 2 0 0 
Women 0 6 12 2 1 0 0 
Total 1 10 21 7 3 0 0 
Proportion 2.4% 23.8% 50% 16.7% 7.1% 0% 0% 
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Table 2. Clinical characteristics and response to C+ECT (defined as improvement (a rating 
of 1, 2 or 3)  on Clinical Global Impression (CGI) -Improvement scale score) 
 Response 
(N=32) 
Non response 
(N=10) 
T-test; p-value 
Age (SD) 46.6 (8.5) 45.5 (7.6) 0.363; 0.718 
Duration of 
illness in 
years(SD) 
5.9 (5.0) 4.3 (5.1) 0.849; 0.401 
Duration of 
clozapine 
treatment in 
years (SD) 
2.6 (3.3) 3.5 (3.2) 0.698; 0.490 
Duration of 
current 
psychotic 
episode 
(months)(SD) 
9.5 (13.4) 8.3 (14.5) 0.246; 0.807 
Mean number 
of ECT 
treatments 
(SD) 
9.9 (4.7) 12.5 (6.6) 1.356; 0.184 
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Table 3 Medication use and association with response to C+ECT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Response 
n= (%) 
No Response 
n= (%) 
X 2; p  
Anticonvulsant use 
Yes 
No 
 
13 (40.6) 
19 (59.4) 
 
2 (20.0) 
8 (80.0) 
 
1.412; 0.212 
Anticonvulsant and 
benzodiazepine use 
Yes 
No  
 
 
16 (51.6) 
15 (48.4) 
 
 
3 (30.0) 
7 (70.0) 
 
 
1.420; 0.205 
Antipsychotic augmentation of 
clozapine 
Yes 
No  
 
 
19 (59.4) 
13 (40.6) 
 
 
4 (40.0) 
6 (60.0) 
 
 
 
1.155; 0.238 
Antidepressant use 
Yes 
No 
 
6 (18.8) 
26 (81.3) 
 
3 (30.0) 
7 (70.0) 
 
0.573; 0.362 
Lithium carbonate use 
Yes 
No 
 
9 (29.0) 
22 (71.0) 
 
3 (30.0) 
7 (70.0) 
 
0.003; 0.622 
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